eXoZymes, Inc. (EXOZ) Stock
eXoZymes stock price chart
EXOZ stock quote & key statistics
eXoZymes annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0 | -$9.2M | -$1.09 |
| FY2024 | $0 | -$5.9M | -$0.24 |
| FY2023 | $0 | -$2.0M | — |
| FY2022 | $0 | -$1.4M | — |
| FY2021 | $0 | -$1.2M | — |
Fiscal year ending December 31. Source: company filings via EODHD.
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
eXoZymes stock FAQ
What is the eXoZymes stock ticker symbol?
eXoZymes, Inc. trades on the NASDAQ under the ticker symbol EXOZ.
What sector and industry is eXoZymes in?
eXoZymes, Inc. is classified in the Healthcare sector, Biotechnology industry.
How many employees does eXoZymes have?
eXoZymes, Inc. has about 32 full-time employees.
What were eXoZymes's revenue and earnings last fiscal year?
eXoZymes reported revenue of $0 and net income of -$9.2M in fiscal 2025, with earnings per share of -$1.09.
When did eXoZymes go public?
eXoZymes stock began trading on November 13, 2024.
Biotechnology stocks
All Healthcare stocks →- ACADACADIA Pharmaceuticals
- ALNYAlnylam
- ARWRArrowhead Pharmaceuticals
- ASNDAscendis Pharma A/S
- BMRNBioMarin Pharmaceutical
- CAICaris Life Sciences
- CORTCorcept Therapeutics
- EXELExelixis
- FTREFortrea
- HALOHalozyme Therapeutics
- HRMYHarmony Biosciences
- INCYIncyte
- IONSIonis Pharmaceuticals
- JAZZJazz Pharmaceuticals
- MDGLMadrigal Pharmaceuticals
- MRNAModerna
- NVAXNovavax
- PTCTPTC Therapeutics
- RAREUltragenyx Pharmaceutical
- REGNRegeneron
- RPRXRoyalty Pharma
- SRPTSarepta Therapeutics
- TECHBio-Techne
- VRTXVertex